Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial.
De Bruycker A, Spiessens A, Dirix P, Koutsouvelis N, Semac I, Liefhooghe N, Gomez-Iturriaga A, Everaerts W, Otte F, Papachristofilou A, Scorsetti M, Shelan M, Siva S, Ameye F, Guckenberger M, Heikkilä R, Putora PM, Zapatero A, Conde-Moreno A, Couñago F, Vanhoutte F, Goetghebeur E, Reynders D, Zilli T, Ost P. De Bruycker A, et al. Among authors: liefhooghe n. BMC Cancer. 2020 May 12;20(1):406. doi: 10.1186/s12885-020-06911-4. BMC Cancer. 2020. PMID: 32398040 Free PMC article. Clinical Trial.
Oligometastatic prostate cancer: The game is afoot.
Lancia A, Zilli T, Achard V, Dirix P, Everaerts W, Gomez-Iturriaga A, Ingrosso G, Liefhooghe N, Miralbell R, Siva S, Van der Eecken K, Ost P. Lancia A, et al. Among authors: liefhooghe n. Cancer Treat Rev. 2019 Feb;73:84-90. doi: 10.1016/j.ctrv.2019.01.005. Epub 2019 Jan 17. Cancer Treat Rev. 2019. PMID: 30684842 Review.
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.
Dirix P, Strijbos M, den Mooter TV, Liefhooghe N, Bruwaene SV, Uvin P, Ghysel C, Ost D, Schatteman P, Bral S, Engels B, den Begin RV, Otte FX, Roumeguere T, Palumbo S, Neybuch Y, Fonteyne V, Ost P, Dirix L. Dirix P, et al. Among authors: liefhooghe n. Future Oncol. 2020 Jun;16(16):1083-1189. doi: 10.2217/fon-2020-0056. Epub 2020 May 1. Future Oncol. 2020. PMID: 32356465
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.
Zilli T, Dirix P, Heikkilä R, Liefhooghe N, Siva S, Gomez-Iturriaga A, Everaerts W, Otte F, Shelan M, Mercier C, Achard V, Thon K, Stellamans K, Moon D, Conde-Moreno A, Papachristofilou A, Scorsetti M, Gückenberger M, Ameye F, Zapatero A, Van De Voorde L, López Campos F, Couñago F, Jaccard M, Spiessens A, Semac I, Vanhoutte F, Goetghebeur E, Reynders D, Ost P. Zilli T, et al. Among authors: liefhooghe n. Eur Urol Focus. 2021 Mar;7(2):241-244. doi: 10.1016/j.euf.2020.12.010. Epub 2020 Dec 29. Eur Urol Focus. 2021. PMID: 33386290 Free article. Clinical Trial.
Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial.
Fonteyne V, Dirix P, Van Praet C, Berghen C, Albersen M, Junius S, Liefhooghe N, Noé L, De Meerleer G, Ost P, Villeirs G, Verbeke S, De Maeseneer D, Rammant E, Verghote F, Elhaseen E, De Man K, Decaestecker K. Fonteyne V, et al. Among authors: liefhooghe n. Eur Urol Focus. 2022 Sep;8(5):1238-1245. doi: 10.1016/j.euf.2021.11.004. Epub 2021 Dec 8. Eur Urol Focus. 2022. PMID: 34893458 Free article. Clinical Trial.
Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.
Achard V, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Meersschout S, Putora PM, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zapatero A, Muto P, Van De Voorde L, Lamanna G, Koutsouvelis N, Dipasquale G, Ost P, Zilli T. Achard V, et al. Among authors: liefhooghe n. Radiother Oncol. 2022 Jul;172:1-9. doi: 10.1016/j.radonc.2022.04.020. Epub 2022 Apr 26. Radiother Oncol. 2022. PMID: 35476942 Free article. Clinical Trial.
Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER Trial.
Fonteyne V, Van Praet C, Ost P, Van Bruwaene S, Liefhooghe N, Berghen C, De Meerleer G, Vanneste B, Verbaeys C, Verbeke S, Lumen N. Fonteyne V, et al. Among authors: liefhooghe n. Eur Urol Focus. 2023 Mar;9(2):317-324. doi: 10.1016/j.euf.2022.09.005. Epub 2022 Sep 23. Eur Urol Focus. 2023. PMID: 36154809 Free article. Clinical Trial.
Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study.
Fonteyne V, Danckaert W, Ost P, Berghen C, Vandecasteele K, Vanneste B, Rans K, Liefhooghe N, Wallaert S, Paelinck L. Fonteyne V, et al. Among authors: liefhooghe n. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231154088. doi: 10.1177/15330338231154088. Technol Cancer Res Treat. 2023. PMID: 37016933 Free PMC article. Clinical Trial.
Subjective, but not objective, cognitive complaints impact long-term quality of life in cancer patients.
Lycke M, Lefebvre T, Pottel L, Pottel H, Ketelaars L, Stellamans K, Van Eygen K, Vergauwe P, Werbrouck P, Cool L, Boterberg T, Liefhooghe N, Schofield P, Debruyne PR. Lycke M, et al. Among authors: liefhooghe n. J Psychosoc Oncol. 2019 Jul-Aug;37(4):427-440. doi: 10.1080/07347332.2018.1504154. Epub 2019 Feb 23. J Psychosoc Oncol. 2019. PMID: 30798774 Clinical Trial.
11 results